1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)propan-1-one | 135132-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)propan-1-one
• 英文别名: 3,4-(difluoromethylenedioxy)propiophenone；1-(2,2-difluoro-benzo[1,3]dioxol-5-yl)propan-1-one；1-(2,2-Difluoro-2H-1,3-benzodioxol-5-yl)propan-1-one；1-(2,2-difluoro-1,3-benzodioxol-5-yl)propan-1-one
• CAS: 135132-40-0
• 化学式: C₁₀H₈F₂O₃
• 分子量: 214.169
• InChiKey: YPIQXQPVQNVXNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)propan-1-one 在 dimethyl sulfide borane 、 (S)-2-甲基-CBS-恶唑硼烷 作用下， 以 二氯甲烷 为溶剂， 以88.3 %的产率得到(R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)propan-1-ol
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
  [FR] COMPOSÉS, COMPOSITIONS ET LEURS MÉTHODES D'UTILISATION

  摘要：

  The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

  公开号：

  WO2023240267A2
• 作为产物：
  描述：

  2,2-二氟-1,3-苯并二恶茂-5-甲醛 在 manganese(IV) oxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 13.0h， 生成 1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)propan-1-one
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF
  [FR] COMPOSÉS, COMPOSITIONS ET LEURS MÉTHODES D'UTILISATION

  摘要：

  The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

  公开号：

  WO2023240267A2

文献信息

• [EN] NEW ANALOGS OF POLYSPHORIN AND USES THEREOF FOR TREATING OR PREVENTING MALARIA<br/>[FR] NOUVEAUX ANALOGUES DE LA POLYSPHORINE ET LEURS UTILISATIONS POUR TRAITER OU PRÉVENIR LA MALARIA
  申请人：ASSIST PUBL HOPITAUX DE PARIS

  公开号：WO2010040730A1

  公开（公告）日：2010-04-15

  The present invention discloses new analogs of polysphorin and their uses as antimalarial drugs which are highly effective in the hepatic phase of the disease. The present invention further discloses a new method for preparing these compounds.

  本发明公开了聚磷胞蛋白的新类似物及其作为抗疟疾药物的用途，这些药物在疟疾的肝脏阶段具有高效性。本发明还公开了一种制备这些化合物的新方法。
• Aralkylamine derivatives, preparation method thereof and fungicides containing the same
  申请人：UBE INDUSTRIES, LTD.

  公开号：EP0424125A3

  公开（公告）日：1991-10-09

  Disclosed is an aralkylamine derivative represented by the following formula (I) and acid addition salt thereof: wherein R₁, R₂, R₃, R₄, R₅, R₆ and n are as described in the description), and preparation method thereof.

  披露了一种由以下公式（I）表示的芳基胺衍生物及其酸盐加合物：其中R₁、R₂、R₃、R₄、R₅、R₆和n如描述中所述），以及其制备方法。
• New analogs of polysphorin and uses thereof for treating or preventing malaria
  申请人：Assistance Publique - Hôpitaux de Paris

  公开号：EP2177496A1

  公开（公告）日：2010-04-21

  The present invention discloses new analogs of polysphorin and their uses as antimalarial drugs which are highly effective in the hepatic phase of the disease. The present invention further discloses a new method for preparing these compounds.

  本发明公开了多鞘氨醇的新类似物及其作为抗疟疾药物的用途，这些类似物对该疾病的肝阶段非常有效。本发明进一步公开了制备这些化合物的新方法。
• Nitrogenated heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10017508B2

  公开（公告）日：2018-07-10

  The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

  本发明提供了一种具有 PDE2A 选择性抑制作用的化合物，该化合物可作为预防或治疗精神分裂症、阿尔茨海默病等的药物。 本发明是一种由式（1）表示的化合物： 其中各符号如说明书所述，或其盐类。
• NITROGENATED HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2848618B1

  公开（公告）日：2018-03-14